• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    6/7/23 1:31:48 PM ET
    $ALLR
    $AVTX
    $CARM
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Avalo Therapeutics (NASDAQ:AVTX) shares rose 17.3% to $3.53 during Wednesday's regular session. The company's market cap stands at $46.5 million.
    • Journey Medical (NASDAQ:DERM) shares rose 15.59% to $1.84. Trading volume for this security as of 13:30 EST is 55.9K, which is 228.4% of its average full-day volume over the last 100 days. The company's market cap stands at $33.3 million.
    • Societal CDMO (NASDAQ:SCTL) shares rose 15.14% to $0.9. Trading volume for Societal CDMO's stock is 81.4K as of 13:30 EST. This is 43.5% of its average full-day volume over the last 100 days. The company's market cap stands at $76.2 million.
    • Microbot Medical (NASDAQ:MBOT) stock moved upwards by 14.79% to $2.56. The current volume of 1.5 million shares is 44.6% of Microbot Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $24.9 million.
    • Mereo BioPharma Group (NASDAQ:MREO) shares moved upwards by 14.78% to $1.32. Trading volume for Mereo BioPharma Group's stock is 3.3 million as of 13:30 EST. This is 194.0% of its average full-day volume over the last 100 days. The company's market cap stands at $164.9 million.
    • Oncology Institute (NASDAQ:TOI) stock rose 14.78% to $0.47. Trading volume for this security as of 13:30 EST is 289.6K, which is 108.5% of its average full-day volume over the last 100 days. The company's market cap stands at $35.4 million.

    Losers

    • PolarityTE (NASDAQ:PTE) shares declined by 43.1% to $0.25 during Wednesday's regular session. PolarityTE's stock is trading at a volume of 2.0 million shares as of 13:30 EST. This is 2960.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.8 million.
    • Vaxart (NASDAQ:VXRT) stock decreased by 28.3% to $0.89. As of 13:30 EST, this security is trading at a volume of 8.3 million shares, making up 547.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $120.5 million.
    • Allarity Therapeutics (NASDAQ:ALLR) stock decreased by 20.05% to $0.19. Trading volume for this security as of 13:30 EST is 3.0 million, which is 91.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.5 million.
    • NewAmsterdam Pharma (NASDAQ:NAMS) stock decreased by 16.16% to $11.55. Trading volume for NewAmsterdam Pharma's stock is 429.0K as of 13:30 EST. This is 1273.7% of its average full-day volume over the last 100 days. The company's market cap stands at $944.4 million.
    • CARISMA Therapeutics (NASDAQ:CARM) stock fell 16.01% to $6.09. Trading volume for CARISMA Therapeutics's stock is 289.3K as of 13:30 EST. This is 160.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $245.1 million.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) shares decreased by 13.78% to $0.76. Trading volume for this security as of 13:30 EST is 449.6K, which is 218.1% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $AVTX
    $CARM
    $DERM

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    NewAmsterdam Pharma Company N.V.
    $NAMS
    3/18/2026$57.00Buy
    Truist
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    More analyst ratings

    $ALLR
    $AVTX
    $CARM
    $DERM
    SEC Filings

    View All

    Vaxart Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vaxart, Inc. (0000072444) (Filer)

    4/23/26 4:45:14 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    4/22/26 8:30:29 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    4/22/26 8:15:32 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

    Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. "We are pleased to welcome Jim to t

    4/23/26 4:30:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®

    Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation Exposure and Improve Ergonomic Issues Impacting Health Practitioners HINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today highlighted that the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), recently released up

    4/22/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

    SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately 85% of all commercial lives in the United States now have access to Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after contracting with the third major group purchasing organization (GPO). Emrosi™ is for the treatment of inflammatory lesions o

    4/21/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $1,225,101 worth of shares (398,985 units at $3.07), increasing direct ownership by 4% to 10,251,929 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/17/26 7:40:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Watson W. Mark bought $8,185 worth of shares (20,000 units at $0.41), increasing direct ownership by 19% to 124,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    12/5/25 5:46:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Heron Elaine J bought $15,921 worth of shares (40,000 units at $0.40), increasing direct ownership by 71% to 96,566 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    11/21/25 1:21:51 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Administrative Officer England Kristin

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    4/23/26 9:25:46 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Clinical Officer Langsam Jeffrey

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    4/23/26 9:24:23 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Kaushal Mohit

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    4/16/26 7:27:23 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma downgraded by Analyst

    Analyst downgraded Mereo BioPharma from Overweight to Neutral

    3/23/26 8:27:06 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

    Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t

    3/25/26 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Leadership Updates

    Live Leadership Updates

    View All

    Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

    Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. "We are pleased to welcome Jim to t

    4/23/26 4:30:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Oncology Institute Names Minh Merchant Chief Legal Officer

    CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors. Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant

    4/6/26 9:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care